{"id":"norelgestromin-ethinyl-estradiol-triphasil","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Breast tenderness"},{"rate":"5-10%","effect":"Mood changes"},{"rate":"5-10%","effect":"Vaginal bleeding irregularities"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Norelgestromin is a progestin that inhibits ovulation by suppressing the release of gonadotropin-releasing hormone, while ethinyl estradiol is an estrogen that thickens cervical mucus and changes the uterine lining to prevent implantation. This combination of actions prevents pregnancy.","oneSentence":"Norelgestromin and ethinyl estradiol work together to prevent ovulation and thicken cervical mucus to prevent sperm from reaching the egg.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:23.144Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception"}]},"trialDetails":[{"nctId":"NCT01044056","phase":"PHASE4","title":"A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03","conditions":"Contraception","enrollment":24},{"nctId":"NCT00511784","phase":"","title":"Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-11","conditions":"Contraception, Female Contraception, Fertility Control","enrollment":440},{"nctId":"NCT00236795","phase":"PHASE3","title":"A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1997-01","conditions":"Contraception, Female Contraception","enrollment":1494}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"norelgestromin + ethinyl estradiol; triphasil.","genericName":"norelgestromin + ethinyl estradiol; triphasil.","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Norelgestromin and ethinyl estradiol work together to prevent ovulation and thicken cervical mucus to prevent sperm from reaching the egg. Used for Contraception.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}